Header Logo

Connection

IRINA AGOULNIK to Male

Back to Details
This is a "connection" page, showing publications IRINA AGOULNIK has written about Male.
IRINA AGOULNIK
Connection Strength
0.402
Male
  1. Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology. Biochem Pharmacol. 2024 09; 227:116401.
    View in: PubMed
    Score: 0.035
  2. Expression patterns and the roles of phosphatidylinositol phosphatases in testis?. Biol Reprod. 2022 10 11; 107(4):902-915.
    View in: PubMed
    Score: 0.032
  3. Androgen Receptor and Poly(ADP-ribose) Glycohydrolase Inhibition Increases Efficiency of Androgen Ablation in Prostate Cancer Cells. Sci Rep. 2020 03 02; 10(1):3836.
    View in: PubMed
    Score: 0.026
  4. Inhibition of base excision repair by natamycin suppresses prostate cancer cell proliferation. Biochimie. 2020 Jan; 168:241-250.
    View in: PubMed
    Score: 0.026
  5. Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. Oncogene. 2019 02; 38(7):1121-1135.
    View in: PubMed
    Score: 0.024
  6. Techniques for Evaluation of AR Transcriptional Output and Recruitment to DNA. Methods Mol Biol. 2018; 1786:219-236.
    View in: PubMed
    Score: 0.023
  7. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clin Cancer Res. 2016 08 01; 22(15):3937-49.
    View in: PubMed
    Score: 0.020
  8. Long-Lasting Consequences of Testosterone Exposure. Endocrinology. 2015 Oct; 156(10):3488-9.
    View in: PubMed
    Score: 0.019
  9. INPP4B suppresses prostate cancer cell invasion. Cell Commun Signal. 2014 Sep 25; 12:61.
    View in: PubMed
    Score: 0.018
  10. Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice. PLoS One. 2013; 8(4):e60455.
    View in: PubMed
    Score: 0.016
  11. Androgen receptor footprint on the way to prostate cancer progression. World J Urol. 2012 Jun; 30(3):279-85.
    View in: PubMed
    Score: 0.015
  12. INPP4B: the new kid on the PI3K block. Oncotarget. 2011 Apr; 2(4):321-8.
    View in: PubMed
    Score: 0.014
  13. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 2011 Jan 15; 71(2):572-82.
    View in: PubMed
    Score: 0.014
  14. Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug; 74(8):669-74.
    View in: PubMed
    Score: 0.012
  15. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol. 2008 Nov; 22(11):2420-32.
    View in: PubMed
    Score: 0.012
  16. Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol. 2008; 617:245-55.
    View in: PubMed
    Score: 0.011
  17. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006 Nov 01; 66(21):10594-602.
    View in: PubMed
    Score: 0.010
  18. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem. 2006 Oct 01; 99(2):362-72.
    View in: PubMed
    Score: 0.010
  19. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 2005 Sep 01; 65(17):7959-67.
    View in: PubMed
    Score: 0.010
  20. Repressors of androgen and progesterone receptor action. J Biol Chem. 2003 Aug 15; 278(33):31136-48.
    View in: PubMed
    Score: 0.008
  21. Discovery of small molecule agonists of the Relaxin Family Peptide Receptor 2. Commun Biol. 2022 11 04; 5(1):1183.
    View in: PubMed
    Score: 0.008
  22. INPP4B protects from metabolic?syndrome and associated disorders. Commun Biol. 2021 03 26; 4(1):416.
    View in: PubMed
    Score: 0.007
  23. Deletion of inositol polyphosphate 4-phosphatase type-II B affects spermatogenesis in mice. PLoS One. 2020; 15(5):e0233163.
    View in: PubMed
    Score: 0.007
  24. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol. 2013 Apr; 45(4):763-72.
    View in: PubMed
    Score: 0.004
  25. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33.
    View in: PubMed
    Score: 0.003
  26. Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci. 2009 Apr; 1160:379-80.
    View in: PubMed
    Score: 0.003
  27. Developmental expression and gene regulation of insulin-like 3 receptor RXFP2 in mouse male reproductive organs. Biol Reprod. 2007 Oct; 77(4):671-80.
    View in: PubMed
    Score: 0.003
  28. Relaxin promotes prostate cancer progression. Clin Cancer Res. 2007 Mar 15; 13(6):1695-702.
    View in: PubMed
    Score: 0.003
  29. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate. 2005 Nov 01; 65(3):276-86.
    View in: PubMed
    Score: 0.002
  30. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005 Sep 01; 64(4):362-72.
    View in: PubMed
    Score: 0.002
  31. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol. 2002 Dec; 16(12):2692-705.
    View in: PubMed
    Score: 0.002
  32. A transgenic insertion upstream of sox9 is associated with dominant XX sex reversal in the mouse. Nat Genet. 2000 Dec; 26(4):490-4.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.